This week in charts: Biotech investors’ China bets are already paying off
This year, companies built around medicines from China have sped toward acquisitions or IPOs. Meanwhile, Summit is no longer the Wall Street darling it was in 2024.
We haven't written up this one. BioPharma Dive has the full story — the link below goes straight to it.